HER-2突变晚期非小细胞肺癌的研究进展  

Progress of Research on Advanced Non-Small Cell Lung Cancer with HER-2 Mutation

作　　者：张良[1] 杨长良 李佩东 程颖[1] ZHANG Liang;YANG Changliang;LI Peidong;CHENG Ying(Department of Thoracic Medical Oncology,Jilin Cancer Hospital,Changchun 130000,China)

机构地区：[1]吉林省肿瘤医院胸部肿瘤内科,长春130000

出　　处：《肿瘤防治研究》2025年第2期87-92,共6页Cancer Research on Prevention and Treatment

基　　金：吉林省科技厅项目(YDZJ202401425ZYTS,20220203150SF)。

摘　　要：近年来,随着抗肿瘤药物研发在非小细胞肺癌(NSCLC)中的快速发展以及高通量测序技术在临床的广泛应用,人表皮生长因子受体-2(HER-2)基因作为NSCLC的一种罕见靶点逐渐引起重视并开展了一系列的探索性研究。传统的化疗以及免疫治疗在HER-2突变人群中疗效并不满意,而抗HER-2单克隆抗体和泛HER抑制剂对生存改善有限。抗体偶联药物(ADC)的发展让HER-2突变NSCLC迎来了转机,以德曲妥珠单抗为代表的新型ADC药物获得了突破,开创了HER-2突变晚期NSCLC精准治疗的新纪元。此外,新型HER-2抑制剂展现了令人鼓舞的初步疗效和安全性,研究正在如火如荼地开展。本文将围绕HER-2突变NSCLC的最新研究进展进行系统综述。Anti-tumor drug research and development in non-small cell lung cancer(NSCLC)is rapidly developing,and the clinical application of high-throughput sequencing technology is also becoming widespread.Accordingly,researchers are focusing on human epidermal growth factor receptor-2(HER-2)gene as a rare target of NSCLC,and a series of exploratory studies has been performed.Traditional chemotherapy and immunotherapy are unsatisfactory in the HER-2 mutant population,whereas the survival improvement of anti-HER-2 monoclonal antibodies and pan-HER inhibitors is limited.The development of antibody drug conjugate(ADC)ushers in a turning point for HER-2-mutated NSCLC,and new ADC drugs represented by trastuzumab deruxtecan are making a breakthrough.It opens up a new era of precision therapy for advanced HER-2-mutated NSCLC.Additionally,novel HER-2 inhibitors show very encouraging initial efficacy and safety,and clinical trials are ongoing.This review focuses on the latest progress of research on HER-2-mutated NSCLC.

关 键 词：非小细胞肺癌 HER-2突变 抗体偶联药物 HER-2抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]